terlipressin hepatorenal syndrome
Selected indexed studies
- Terlipressin for hepatorenal syndrome. (Curr Opin Gastroenterol, 2024) [PMID:38353275]
- Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. (N Engl J Med, 2021) [PMID:33657294]
- Hepatorenal Syndrome. (Clin J Am Soc Nephrol, 2019) [PMID:30996046]
_Worker-drafted node — pending editorial review._
Connections
terlipressin hepatorenal syndrome is a side effect of
Sources
- Diagnosis and Management of Cirrhosis and Its Complications: A Review. (2023) pubmed
- Terlipressin for hepatorenal syndrome. (2024) pubmed
- Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. (2021) pubmed
- Hepatorenal Syndrome. (2019) pubmed
- Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment. (2023) pubmed
- Hepatorenal Syndrome in Cirrhosis. (2024) pubmed
- Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. (2016) pubmed
- Terlipressin for hepatorenal syndrome. (2012) pubmed
- Update on Hepatorenal Syndrome: From Pathophysiology to Treatment. (2025) pubmed
- Terlipressin for hepatorenal syndrome. (2006) pubmed